Urol. praxi. 2016;17(3):102-105 | DOI: 10.36290/uro.2016.027

Systemic treatment for bladder cancer

doc. MUDr. Tomáš Büchler, Ph.D.
Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

Systemic treatment for bladder cancer is indicated in four clinical situations, including neoadjuvant therapy prior to radical

cystectomy for muscle-invasive bladder cancer, adjuvant chemotherapy after cystectomy for muscle-invasive bladder cancer,

as a part of bladder sparing protocols in concomitance with radiotherapy, and for treatment of advanced or metastatic disease.

Chemotherapy regimens containing cisplatin are the basis of current systemic therapies for bladder cancer.

Keywords: bladder cancer, chemotherapy, cisplatin

Published: August 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Büchler T. Systemic treatment for bladder cancer. Urol. praxi. 2016;17(3):102-105. doi: 10.36290/uro.2016.027.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dušek L, Mužík J, Kubásek M, et al. Epidemiologie zhoubných nádorů v České republice [online]. Masarykova univerzita, [2005], [cit. 2015-12-30]. http://www.svod.cz.
    2. Teply BA, Kim JJ. Systemic therapy for bladder cancer - a medical oncologist's perspective. J Solid Tumors 2014; 4: 25-35. Go to original source...
    3. Novotná J, Vítek P a kol. Onkologie v klinické praxi. Mladá Fronta, Praha 2012.
    4. Advanced Bladder Cancer Meta-Analysis (2005). Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 48: 202-205. Go to PubMed...
    5. Bladder Cancer. NCCN Guidelines Version 2.2015. http://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf
    6. Zhoubný novotvar močového měchýře (C67). Modrá kniha České onkologické společnosti. Platnost od 1. 9. 2015. http://www.linkos.cz/informace-pro-praxi/modra-kniha/22-zhoubny-novotvar-mocoveho-mechyre-c67/
    7. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol. 2005; 48: 189-199. Go to PubMed...
    8. Sternberg CN, Skoneczna I, Kerst JM, et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol 2015; 16: 76-86. Go to original source... Go to PubMed...
    9. Ploussard G, Daneshmand S, Efstathiou JA, et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol 2014; 66: 120-137. Go to original source... Go to PubMed...
    10. De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012; 30: 191-199. Go to original source... Go to PubMed...
    11. Stadler WM, Kuzel T, Roth B, et al. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol. 1997; 15: 3394-3398. Go to original source... Go to PubMed...
    12. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23: 4602-4608. Go to original source... Go to PubMed...
    13. Sternberg CN, de Mulder P, Schornagel JH, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006; 42: 50-54. Go to original source... Go to PubMed...
    14. Bellmunt J, Théodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009; 27: 4454-4461. Go to original source... Go to PubMed...
    15. Hahn NM, Stadler WM, Zon RT, et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol 2011; 29: 1525-1530. Go to original source...
    16. Knollman H, Godwin JL, Jain R, Wong YN, Plimack ER, Geynisman DM. Muscle-invasive urothelial bladder cancer: an update on systemic therapy. Ther Adv Urol 2015; 7: 312-330. Go to original source...
    17. Witjes JA, Compérat E, Cowan NC, et al. Guidelines on Muscle-invasive and Metastatic Bladder Cancer. WWW: http://http://uroweb.org/wp-content/uploads/EAU-Guidelines-Muscle-invasive-and-Metastatic-Bladder-Cancer-2015-v1.pdf (Přístup 7. 2. 2016).
    18. Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps FA. Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4,PD-1/PD-L1, and HLA-G. Eur Urol 2015; 68: 267-279. Go to original source... Go to PubMed...
    19. Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014; 515: 558-562. Go to original source...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.